Publications by authors named "A S Griffith"

The research-to-practice gap is a well-known phenomenon. The adoption of evidence into clinical practice needs to consider the complexity of the health care system and a multitude of contextual issues. Research evidence is usually a form of extrinsic motivation for practice change, but works best when it aligns with the intrinsic values of the system and the people in it.

View Article and Find Full Text PDF

Background: Nuclear factor kappa B (NF-κB) c-Rel is a psoriasis susceptibility locus, however mechanisms underlying c-Rel transactivation during disease are poorly understood. Inflammation in psoriasis can be triggered following Toll-like Receptor 7 (TLR7) signalling in dendritic cells (DCs), and c-Rel is a critical regulator of DC function. Here, we studied the mechanism of TLR7-induced c-Rel-mediated inflammation in DCs.

View Article and Find Full Text PDF
Article Synopsis
  • The study focused on invasive group A Streptococcus trends in Canada by analyzing emm1 isolates from 2018 to 2023.
  • There was a notable rise in hypervirulent M1 lineage isolates, increasing from 22.1% to 60.2% during this period.
  • Genomic analysis revealed clusters linked to specific locations and times, as well as genes tied to the acquisition of virulent bacteriophages.
View Article and Find Full Text PDF
Article Synopsis
  • Decreased activity of the SLC26A4 protein, critical for ear fluid balance, is linked to hearing loss.
  • Researchers found that the μ2 subunit of the AP-2 complex plays a key role in controlling SLC26A4's presence at the cell membrane where it helps reabsorb endolymph in the inner ear.
  • By blocking clathrin-mediated endocytosis, they showed that more SLC26A4 accumulates on cell surfaces, suggesting that the SLC26A4-μ2 interaction directly influences how much SLC26A4 is available where it’s needed.
View Article and Find Full Text PDF

Aficamten, a cardiac myosin inhibitor, is being developed for the treatment of patients with symptomatic hypertrophic cardiomyopathy (HCM). The purpose of this study was to determine the absorption, metabolism, and excretion of aficamten. Eight healthy male participants received a single oral dose of 20 mg aficamten (containing approximately 100 μCi of radiocarbon).

View Article and Find Full Text PDF